
Please try another search
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Name | Age | Since | Title |
---|---|---|---|
Michael Quigley | - | 2021 | Director |
Antoni Ribas | 57 | 2019 | Independent Director & Member of Scientific Advisory Board |
Jeffrey A. Bluestone | 71 | - | Chairman of Scientific Advisory Board |
Kathryn E. Falberg | 63 | 2017 | Independent Director |
David L. Lacey | 72 | 2020 | Independent Director & Member of Scientific Advisory Board |
C. Patrick Machado | 60 | 2019 | Independent Director |
Yasunori Kaneko | 71 | 2015 | Lead Independent Director |
Terry J. Rosen | 64 | 2015 | Co-Founder, Chairman & CEO |
K. Christopher Garcia | - | - | Co-Founder & Member of Scientific Advisory Board |
Stefani Spranger | - | 2020 | Member of Scientific Advisory Board |
Linda Slanec Higgins | 63 | 2021 | Member of Scientific Advisory Board & Director |
Johanna Mercier | 55 | 2024 | Director |
Nicole Lambert | 51 | 2021 | Independent Director |
Andrew J. Perlman | 77 | 2020 | Independent Director |
Andrew Perlman | - | 2020 | - |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review